NDAINTRAVENOUSSOLUTION
Approved
Mar 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NEURACEQ (florbetaben f 18) by Remedy Plan Therapeutics is positron emitting activity [moa]. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEURACEQ (florbetaben F 18) is a positron-emitting radioactive diagnostic agent administered intravenously as a solution. It is used in PET imaging to detect amyloid pathology in the brain, primarily for cognitive impairment evaluation. The drug works through positron emission activity to visualize amyloid-beta accumulation in Alzheimer's disease and related conditions.
Peak6.2 years to LOE
Peak-stage diagnostic product with minimal competitive pressure suggests stable market position but limited growth opportunities for commercial expansion teams.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEURACEQ offers limited publicly linked job opportunities, reflecting its niche diagnostic positioning and narrow commercial footprint. Roles would primarily involve maintaining stable market presence rather than driving growth or launch activities.
Product ManagerMedical Science Liaison
Worked on NEURACEQ at Remedy Plan Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.